RON Biomarker Predicts Protein Kinase Inhibitor Sensitivity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current anticancer drugs show significant individual variability in efficacy and resistance, making it challenging to predict sensitivity in cancer cells, particularly for colon cancer, due to complex in-vivo reactions and diverse treatment options.

Innovation Solution

Development of a biomarker using active Recepteur d'Origine Nantais (RON) variants and mutants to predict sensitivity to protein kinase inhibitors, including measuring the expression levels of RON for determining drug effectiveness in colon cancer treatment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional anticancer drugs are used, then cancer treatment is provided, but individual variability in efficacy and resistance makes it challenging to predict sensitivity

Engineering Contradiction:

Improvepredictability of drug sensitivityVSAvoidcomplexity of in-vivo reactions

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent introduces RON expression level as an intermediary biomarker that mediates between the complex in-vivo reactions and the drug sensitivity prediction. By measuring RON expression levels in cancer cells, the system provides a measurable intermediate parameter that correlates with drug response, thereby improving predictability without requiring direct observation of complex cellular reactions.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the approach from observing complex in-vivo reactions to measuring a specific parameter (RON expression level). This parameter change simplifies the prediction process by focusing on a quantifiable molecular characteristic that varies with drug sensitivity, transforming an unmanageably complex problem into a measurable parameter-based prediction system.

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If cancer cells are treated with drugs after separating from biopsy tissue, then drug effectiveness can be measured, but the process is time-consuming and complex

Engineering Contradiction:

Improvemeasurement of drug sensitivityVSAvoidtime for treatment and measurement process

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent applies preliminary action by measuring RON expression levels in cancer cells obtained from biopsy tissue before the actual drug treatment. This preliminary measurement of the biomarker allows prediction of drug sensitivity in advance, eliminating the need to wait for post-treatment measurements and significantly reducing the time required for effectiveness assessment.

Inventive Principle:

Principle #10Preliminary action

3Reliability

If multiple cancer cell lines are tested for drug sensitivity, then comprehensive data is obtained, but the complexity and cost increase

Engineering Contradiction:

Improvecomprehensive drug sensitivity dataVSAvoidcomplexity of testing multiple cell lines

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts the essential predictive information from the complex testing of multiple cancer cell lines by focusing solely on RON expression level measurement. Instead of testing numerous cell lines comprehensively, the system extracts and measures only the RON expression parameter, which serves as a reliable predictor of drug sensitivity, thereby reducing complexity while maintaining reliability.

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS11946934B2Biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof

Publication Date: 2024.04.02 WELLMARKER BIO CO LTD

AI summary

The present disclosure relates to a biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof. The present disclosure provides a marker, a composition, and a kit for predicting the sensitivity to a protein kinase inhibitor, and a prediction method thereof. According to the present disclosure, the marker has an excellent effect of predicting the sensitivity to a protein kinase inhibitor, and thus the present disclosure can be useful for cancer treatment.